Novo Nordisk is in talks with healthcare providers about innovative pricing models for its Wegovy weight loss drug, The Financial Times’ Hannah Kuchler and Richard Milne reports. CEO Lars Fruergaard Jorgensen tells the FT that the company is willing to be “flexible” on pricing schemes “to make it possible to adopt medicines upfront, see the benefits and pay down the road.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk (NYSE:NVO) Falls as Large Investor Offloads Shares
- Unusually active option classes on open November 24th
- Novo Nordisk (NYSE:NVO) Set to Introduce Wegovy in Asia
- Novo Nordisk invests more than 16B Danish kroner in production in France
- Novo Nordisk (NYSE:NVO) Pours $2.3B into Expanding Production in France